{"id":"W2201190784","doi":"10.1056/nejmoa1505654","title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1320,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Progression-free survival; Oncology; Neutropenia; Hazard ratio; Bortezomib; Dexamethasone; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09997258122392107,"score_gpt":0.365146460681726,"score_spread":0.265173879457805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}